Anthem biosciences Limited has announced the resignation of its General Counsel, Mr. K. Ramakrishnan, who will step down from his position effective March 31, 2026. The resignation was formally submitted on March 13, 2026, marking the end of a nearly two-decade association with the pharmaceutical company.

Senior Management Departure

Mr. Ramakrishnan has been with Anthem Biosciences since February 17, 2007, serving in various capacities before being appointed as General Counsel. His role was elevated to Senior Management Personnel status pursuant to Regulation 16 of SEBI LODR Regulations during the Board Meeting held on November 5, 2024.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and National Stock Exchange of India Limited, with the disclosure also made available on the company's official website.

Company Secretary and Compliance Officer Divya Prasad signed the regulatory filing, ensuring compliance with the Master Circular SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Transition Details

In his resignation letter addressed to Managing Director Ajay Bhardwaj, Mr. Ramakrishnan expressed gratitude for the opportunities provided during his tenure. He cited his superannuation and the company's recent listing as factors influencing his decision to step down from the role.

Upon his cessation from the General Counsel position, Mr. Ramakrishnan will also cease to be classified as a member of the Senior Management Personnel of the company. The transition is scheduled to be completed by the close of business on March 31, 2026.

Anthem Biosciences Limited has executed a First Amendment to its loan agreement with wholly owned subsidiary Neoanthem Lifesciences Private Limited, enabling the conversion of an additional Rs 275,00,00,000 into equity shares. The amendment was executed on February 23, 2026, as part of the company's ongoing financial restructuring with its subsidiary.

Amendment Details and Financial Structure

The First Amendment modifies the original loan agreement dated April 15, 2024, which initially provided for financial assistance of up to Rs 300,00,00,000 with an option to convert Rs 100,00,00,000 into equity shares. The overall financial assistance limit was subsequently enhanced to Rs 550,00,00,000 pursuant to a Board Resolution dated June 27, 2024.

Previous Conversion and Approvals

Under the original agreement terms, Rs 100,00,00,000 was successfully converted into equity shares on February 21, 2025, following requisite approvals from the Board and shareholders of Neoanthem. The current amendment provides for conversion of an additional Rs 275,00,00,000 at the company's discretion, subject to applicable approvals.

The transaction qualifies as a Material Related Party Transaction under the Companies Act, 2013 and SEBI LODR Regulations, 2015. Necessary approvals were obtained from the Audit Committee and Board of Directors on June 9, 2025, and from shareholders at the Annual General Meeting held on June 10, 2025.

Key Terms and Conditions

The amendment maintains the unsecured nature of the loan while providing flexibility for equity conversion. Key features include:

• Conversion at company's discretion within the sanctioned limit
• Valuation based on registered valuer's report at time of allotment
• Compliance with applicable laws and regulations
• No security required as it remains an unsecured facility

Corporate Governance and Related Party Disclosures

Neoanthem Lifesciences Private Limited is a wholly owned subsidiary of Anthem Biosciences, with common directors including Mr. Ajay Bhardwaj (Managing Director), Mr. Ganesh Sambasivam (Whole-time Director), and Mr. K. C. Ravindra (Whole-time Director) serving on both boards.

The transaction is conducted on an arm's length basis with no nominee directors appointed pursuant to the agreement. Upon exercise of the conversion option, the loan exposure of Rs 275,00,00,000 in the company's books would be reduced while investment in Neoanthem would increase correspondingly on a standalone basis, with no material impact expected on consolidated financial statements.